Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Capital Expenditures (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Capital Expenditures for 17 consecutive years, with $17.2 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 41.84% to $17.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $81.4 million through Dec 2025, down 22.01% year-over-year, with the annual reading at $81.4 million for FY2025, 22.01% down from the prior year.
  • Capital Expenditures hit $17.2 million in Q4 2025 for Integra Lifesciences Holdings, up from $15.2 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $29.7 million in Q2 2024 to a low of $6.6 million in Q2 2021.
  • Historically, Capital Expenditures has averaged $17.2 million across 5 years, with a median of $15.3 million in 2024.
  • Biggest YoY gain for Capital Expenditures was 225.47% in 2021; the steepest drop was 59.59% in 2021.
  • Year by year, Capital Expenditures stood at $27.4 million in 2021, then tumbled by 47.29% to $14.5 million in 2022, then surged by 69.72% to $24.5 million in 2023, then increased by 20.64% to $29.6 million in 2024, then crashed by 41.84% to $17.2 million in 2025.
  • Business Quant data shows Capital Expenditures for IART at $17.2 million in Q4 2025, $15.2 million in Q3 2025, and $20.1 million in Q2 2025.